Syros to Present at the 35th Annual J.P. Morgan Healthcare Conference
Syros Pharmaceuticals (NASDAQ: SYRS), a biopharmaceutical company pioneering the development of medicines to control the
expression of disease-driving genes, today announced that its Chief Executive Officer Nancy Simonian, M.D., will present a
corporate overview at the 35th Annual J.P. Morgan Healthcare Conference. Details are as follows:
35th Annual J.P. Morgan Healthcare Conference
Date: Wednesday, January 11
Time: 3 p.m. PT (6 p.m. ET)
Location: Westin St. Francis Hotel, 335 Powell Street., San Francisco, CA
The presentation will be followed by a question and answer session.
A live webcast of the presentation and question and answer session can be accessed under Events & Presentations in the News
and Investors section of the Company's website at www.syros.com. A downloadable copy of the corporate slide presentation is also available on the News and
Investors section of the website. A replay of the webcast will be archived on the website for approximately 30 days following the
presentation.
About Syros Pharmaceuticals
Syros Pharmaceuticals is pioneering the understanding of the non-coding region of the genome to advance a new wave of medicines
that control expression of disease-driving genes. Syros has built a proprietary platform that is designed to systematically and
efficiently analyze this unexploited region of DNA in human disease tissue to identify and drug novel targets linked to genomically
defined patient populations. Because gene expression is fundamental to the function of all cells, Syros’ gene control platform
has broad potential to create medicines that achieve profound and durable benefit across a range of diseases. Syros is
currently focused on cancer and immune-mediated diseases and is advancing a growing pipeline of gene control medicines. Syros’ lead
drug candidates are SY-1425, a selective RARα agonist in a Phase 2 clinical trial for genomically defined subsets of patients with
acute myeloid leukemia and myelodysplastic syndrome, and SY-1365, a selective CDK7 inhibitor with potential in a range of solid
tumors and blood cancers. Led by a team with deep experience in drug discovery, development and commercialization, Syros is located
in Cambridge, Mass.
Media Contact:
Syros Pharmaceuticals, Inc.
Naomi Aoki, 617-283-4298
naoki@syros.com
or
Investor Contact:
Stern Investor Relations, Inc.
Hannah Deresiewicz, 212-362-1200
hannahd@sternir.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170110005978/en/